课题基金 / 基金详情

PHASE II STUDY OF INTERMITTENT RECOMBINANT HUMAN INTERLEUKIN-2 BY INTRAVENOUSLY

PHASE II STUDY OF INTERMITTENT RECOMBINANT HUMAN INTERLEUKIN-2 BY INTRAVENOUSLY
间歇性静脉注射重组人白介素-2 的 II 期研究
批准号：
6118449
负责人：
RONALD T. MITSUYASU
金额：
$0.19万
依托单位：
UNIVERSITY OF CALIFORNIA LOS ANGELES
依托单位国家：
美国
项目类别：
财政年份：
1998
资助国家：
美国
项目状态：
已结题
起止时间：
1998-12-01 至 1999-11-30
来源：
https://reporter.nih.gov/project-details/6118449
关键词：
AIDS therapy CD4 molecule antiAIDS agent antiviral agents clinical research clinical trial phase I drug administration rate /duration drug administration routes drug screening /evaluation drug tolerance human subject human therapy evaluation interleukin 2 intravenous administration leukocyte count microorganism disease chemotherapy quality of life recombinant proteins

项目摘要

项目成果

RONALD T. MITSUYASU的其他基金

相似基金

相关文献

中文摘要
翻译
比较两种不同的间歇给予rhIL-2和高活性抗逆转录病毒治疗方案的途径与单独使用高活性抗逆转录病毒治疗的途径，在1年的rhIL-2治疗后，CD4计数比随机化前基线值增加大于或等于50%的受试者比例和CD4计数变化率。本研究将比较这些治疗方案的安全性、耐受性和对生活质量的影响。
英文摘要
To compare two different routes of intermittently administered rhIL-2 with a highly active antiretroviral regimen to highly active antiretroviral therapy alone with respect to the proportion of subjects achieving greater than or equal to 50% increase in CD4 counts above prerandomization baseline values after one year of rhIL-2 and the rate of change in CD4 counts. This study will compare the safety, tolerance, and effect on quality of life of these regimens.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Studies on the Prevalence, Risk Factors and Outcomes of Cancers in HIV in India
Studies on the Prevalence, Risk Factors and Outcomes of Cancers in HIV in India
South American Prevention of HIV Research Training Program (SAPHIR)
South American Prevention of HIV Research Training Program (SAPHIR)
海外基金